Company intelligence / Profile preview

Cell>Point

Colorado, United States

Ownership: Private
Development stage: Other

Overview

Cell>Point developed diagnostic radiopharmaceuticals to address unmet needs in cancer and cardiac imaging. Their lead product, 99m-Tc-Ethylenedicysteine-glucosamine (99mTc-EC-DG), achieved Phase 3 status for lung cancer imaging and coronary artery disease diagnostics; comparative studies showed non-inferior performance to standard PET/CT agents (18F-FDG). No commercial launches appear complete; company has faced legal/SEC issues halting activity

Therapeutic areas: OncologyInfectious DiseasesCardiovascular
Modalities: RadiopharmaceuticalSmall molecule
Industry: Medical Imaging

Partnerships

Licensed five platform technologies from The University of Texas MD Anderson Cancer Center

Beyond the preview

Go deeper on Cell>Point.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell>Point.

Explore the full profile